Stock Track | Arcutis Biotherapeutics Soars 5.52% After-Hours on Strong Q4 Earnings Beat and Raised 2026 Guidance

Stock Track09:09

Arcutis Biotherapeutics Inc. (ARQT) saw its stock price soar 5.52% in after-hours trading on Wednesday, following the release of its fourth quarter and full year 2025 financial results.

The biopharmaceutical company reported a significant swing to profitability, with Q4 earnings of $0.13 per share compared to a loss of $0.09 per share in the same period last year, beating analyst estimates. Revenue for the quarter reached $129.5 million, representing an 81.5% year-over-year increase and also surpassing expectations. The strong performance was primarily driven by robust demand for the company's ZORYVE product, with net product revenue climbing 84% year-over-year.

Arcutis also raised its full-year 2026 net product revenue guidance to $480-$495 million, up from previous guidance of $455-$470 million. The company reported achieving positive operating cash flow in Q4 2025 and anticipates maintaining this trend going forward. Additional business updates included Medicare access beginning in January 2026 and recent FDA approval for ZORYVE cream 0.05% for atopic dermatitis in children ages 2 to 5.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1101088398?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-26 09:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1101088398","market":"sg","top_or_hot":-1,"title":"Stock Track | Arcutis Biotherapeutics Soars 5.52% After-Hours on Strong Q4 Earnings Beat and Raised 2026 Guidance","media":"Stock Track","content":"<p>Arcutis Biotherapeutics Inc. (ARQT) saw its stock price soar 5.52% in after-hours trading on Wednesday, following the release of its fourth quarter and full year 2025 financial results.</p><p>The biopharmaceutical company reported a significant swing to profitability, with Q4 earnings of $0.13 per share compared to a loss of $0.09 per share in the same period last year, beating analyst estimates. Revenue for the quarter reached $129.5 million, representing an 81.5% year-over-year increase and also surpassing expectations. The strong performance was primarily driven by robust demand for the company's ZORYVE product, with net product revenue climbing 84% year-over-year.</p><p>Arcutis also raised its full-year 2026 net product revenue guidance to $480-$495 million, up from previous guidance of $455-$470 million. The company reported achieving positive operating cash flow in Q4 2025 and anticipates maintaining this trend going forward. Additional business updates included Medicare access beginning in January 2026 and recent FDA approval for ZORYVE cream 0.05% for atopic dermatitis in children ages 2 to 5.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Arcutis Biotherapeutics Soars 5.52% After-Hours on Strong Q4 Earnings Beat and Raised 2026 Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Arcutis Biotherapeutics Soars 5.52% After-Hours on Strong Q4 Earnings Beat and Raised 2026 Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-26 09:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Arcutis Biotherapeutics Inc. (ARQT) saw its stock price soar 5.52% in after-hours trading on Wednesday, following the release of its fourth quarter and full year 2025 financial results.</p><p>The biopharmaceutical company reported a significant swing to profitability, with Q4 earnings of $0.13 per share compared to a loss of $0.09 per share in the same period last year, beating analyst estimates. Revenue for the quarter reached $129.5 million, representing an 81.5% year-over-year increase and also surpassing expectations. The strong performance was primarily driven by robust demand for the company's ZORYVE product, with net product revenue climbing 84% year-over-year.</p><p>Arcutis also raised its full-year 2026 net product revenue guidance to $480-$495 million, up from previous guidance of $455-$470 million. The company reported achieving positive operating cash flow in Q4 2025 and anticipates maintaining this trend going forward. Additional business updates included Medicare access beginning in January 2026 and recent FDA approval for ZORYVE cream 0.05% for atopic dermatitis in children ages 2 to 5.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARQT","symbol_name":"Arcutis Biotherapeutics Inc.","start_time":0,"source_url":"","article_id":"1101088398","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1101088398","pubTimestamp":1772068171,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Arcutis Biotherapeutics Inc. (ARQT) saw its stock price soar 5.52% in after-hours trading on Wednesday, following the release of its fourth quarter and full year 2025 financial results.The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ARQT":"Arcutis Biotherapeutics Inc."},"translate_title":"股票追踪|Arcutis Biotherapeutics盘后飙升5.52%，第四季度盈利强劲，并上调2026年指引","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARQT":1},"content_text":"Arcutis Biotherapeutics Inc. (ARQT) saw its stock price soar 5.52% in after-hours trading on Wednesday, following the release of its fourth quarter and full year 2025 financial results.The biopharmaceutical company reported a significant swing to profitability, with Q4 earnings of $0.13 per share compared to a loss of $0.09 per share in the same period last year, beating analyst estimates. Revenue for the quarter reached $129.5 million, representing an 81.5% year-over-year increase and also surpassing expectations. The strong performance was primarily driven by robust demand for the company's ZORYVE product, with net product revenue climbing 84% year-over-year.Arcutis also raised its full-year 2026 net product revenue guidance to $480-$495 million, up from previous guidance of $455-$470 million. The company reported achieving positive operating cash flow in Q4 2025 and anticipates maintaining this trend going forward. Additional business updates included Medicare access beginning in January 2026 and recent FDA approval for ZORYVE cream 0.05% for atopic dermatitis in children ages 2 to 5.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1101088398","isCrawlerRequest":true}